Zhenhua HUANG, MBA, M.S. (Chairman and President)
Mr. Huang has an MBA degree and a M.S. degree in pharmaceutics. He has more than 16 years of R&D as well as manufacturing experience in pharmaceutical industry with solid track records of business success in China. Early in 1996, Mr. Huang founded and operated several pharmaceutical companies dedicated to bringing generic drugs to the Chinese market. In 2002, he founded Xuan Zhu Pharma (former parent company of KBP Biosciences) that focused on developing antibiotics and other generic medicine in China. His organization was regarded as one of the top firms, based on the number of generic drugs developed, in China.
Continuing his success in Xuan Zhu Pharma, Mr. Huang steered his companies into the arena of new drug discovery and development in 2005. Since then, he has built both a strong platform for new drug discovery and a talented R&D team through series founding of KBP Biosciences (Singapore) in 2010 and KBP Biosciences (China) in 2011. Since 2012, Mr. Huang has served as the CEO and President of the companies.
Mr. Huang has a vision that KBP Biosciences will provide world class new drug discovery programs and eventually the medicines for unmet medical needs across the world.
Li LONG, MD., Ph.D.(Vice President of Pharmacology)
Dr. Long graduated from The 3rd Military Medical College, China with an MD degree in 1983 and practiced as general surgeon. He obtained his Ph.D. degree in tumor biology from McGill University, Montreal, Canada followed by post doctoral training at Albert Einstein College of Medicine, Bronx, New York. Dr. Long has more than 30 years experience in medical practice and research and has worked in the field of pharmacology and translational medicine for more than 14 years in biotech and pharmaceutical industry.
Prior to KBP BioSciences, Dr. Long has served as Associate Director at FivePrime Therapeutics, Research Investigator II at Novartis Institutes for Biomedical Research, Principal Scientist at Chiron Corporation and Sr. Research Scientist at Aventis.
Koji Matsuyama, Ph.D.(Director of Clinical Development)
Dr. Matsuyama obtained his Ph.D. degree in life sciences from The University of Tokyo. He has over 6 years of industry experience in clinical development, working previously with Terumo and Astellas in Japan. Dr. Matsuyama is very familiar with GCP and ICH regulations.